Search

Author/Creator Colombo, M.P.

1. Gene expression profile at week 2 of neoadjuvant therapy course predicts outcome in HER2-positive breast cancer patients: an explorative analysis from NeoALTTO. (November 2022)

Authors:
Di Cosimo, S.; Pizzamiglio, S.; Sotiriou, C.; Ciniselli, C.M.; Triulzi, T.; de Cecco, L.; El-Abed, S.; Izquierdo, M.; de Azambuja, E.; Saura, C.; Huober, J.; Untch, M.; Lang, I.; Loi, S.; Tagliabue, E.; Rubio, I.T.; Vingiani, A.; Colombo, M.P.; Verderio, P.; Pruneri, G.
Journal:
European journal of cancer
Issue:
Volume 175(2022)Supplement 1
Page Start:
S78
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 25P Platinum-based chemotherapy (PCT) addition to first-line PD-1/PD-L1 inhibitors (ICI) prevent hyperprogressive disease (HPD) in non-small cell lung cancer (NSCLC) patients (pts) by reducing circulating immature neutrophils. (December 2022)

Authors:
Ferrara, R.; Lo Russo, G.; Ciniselli, C.M.; Bassani, B.; Calareso, G.; Duroni, V.; Di Gregorio, S.; Proto, C.; Prelaj, A.; De Toma, A.; Occhipinti, M.; Brambilla, M.; Manglaviti, S.; Mazzeo, L.; Ganzinelli, M.; De Braud, F.G.M.; Garassino, M.C.; Colombo, M.P.; Verderio, P.; Sangaletti, S.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. (May 2019)

Authors:
Proto, C.; Ferrara, R.; Signorelli, D.; Lo Russo, G.; Galli, G.; Imbimbo, M.; Prelaj, A.; Zilembo, N.; Ganzinelli, M.; Pallavicini, L.M.; De Simone, I.; Colombo, M.P.; Sica, A.; Torri, V.; Garassino, M.C.
Journal:
Cancer treatment reviews
Issue:
Volume 75(2019)
Page Start:
39
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗